-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original title: Rhine Biosciences: Announcement of investor relations activity records was released on June 29, and 19 institutions including Guoyuan Securities and Hongtu Innovation Fund participated
On July 1, 2022, Rhine Biotech (002166) issued an announcement on the record of investor relations activities.
The details are as follows:
Q: How is the company's industrial hemp project progressing? What are the advantages?
Q: How is the company's industrial hemp project progressing? What are the advantages?A: The optimization and debugging of the company's industrial hemp project is progressing smoothly
Q: How will the passage of the US MORE Act affect companies?
Q: How will the passage of the US MORE Act affect companies?A: If the US House of Representatives MORE Act is passed, it will be good for the entire industry.
Q: The prospects of the industrial hemp industry are so good, why are there no larger players in the extraction field in the United States? Could the company introduce the business layout of industrial hemp in the United States, as well as the outlook for orders and business plans?
Q: The prospects of the industrial hemp industry are so good, why are there no larger players in the extraction field in the United States? Could the company introduce the business layout of industrial hemp in the United States, as well as the outlook for orders and business plans?A: Nearly 70% of the world's plant extraction production capacity is located in China.
Q: What are the current major competitors of natural sweeteners?
Q: What are the current major competitors of natural sweeteners?A: From a global perspective, the current competitors of the company's natural sweeteners mainly include two, the overseas company PureCircle, which was acquired by Ingredion in the United States and has been privatized, and the domestic Zhucheng Haotian (non-listed).
Q: Can you introduce the cooperation between the company and Firmenich? How to ensure that the company can still have stable demand for orders after the contract ends?
Q: Can you introduce the cooperation between the company and Firmenich? How to ensure that the company can still have stable demand for orders after the contract ends?A: The company and Firmenich cooperate on a strategic level.
Q: Where is the ceiling of the natural sweetener industry? What is the difference between domestic and foreign sugar substitute applications?
Q: Where is the ceiling of the natural sweetener industry? What is the difference between domestic and foreign sugar substitute applications?A: The natural sweetener business, as a category that has just emerged for more than ten years, I think it is too early to talk about the ceiling of the industry
Q: What is the company's ability to control and negotiate the price of natural sweetener raw materials? How has the price of raw materials fluctuated in recent years? Does the price increase have a big impact on the company?
Q: What is the company's ability to control and negotiate the price of natural sweetener raw materials? How has the price of raw materials fluctuated in recent years? Does the price increase have a big impact on the company?A: Through years of selection of raw material partners and accumulation of high-quality suppliers, the company now has a strong ability to control raw material procurement, and has formed a complete management system from the source of seedlings to field management, and even procurement and transportation
The main business of Rhine Biotech is the production of high-purity monomers and standardized extracts of plant functional ingredients such as mogrosides, proanthocyanidins, anthocyanins, and Lycium barbarum polysaccharides
According to the 2022 quarterly report of Rhine Biosciences, the company's main income was 282 million yuan, up 27.
The stock has been rated by 5 institutions in the last 90 days, 4 with buy rating and 1 with overweight rating
The following is the detailed profit forecast information:
Margin financing and securities lending data show that the stock has a net inflow of 105 million in financing in the past three months, and the financing balance has increased
The above content is organized by Securities Star based on public information.
Editor:
